Skip to content

Global Health Equity

GHE Header Desktop

As the world’s largest healthcare company, Johnson & Johnson has a unique ability to apply its expertise and convening power to advance progress on some of the most difficult global health challenges. We strive to create long-term social value through delivering innovative medicines, vaccines, treatments and devices; improving access and affordability; supporting efforts to create stronger healthcare systems; and helping put a healthy mind, body and environment within reach of everyone, everywhere.

Our commitment to advancing global health equity incorporates our active efforts and collaborations to enhance access to medical treatment and healthcare for all people while breaking down historic racial and social barriers that hinder access to equitable healthcare solutions. Similarly, we contribute to increasing the resilience and capabilities of health systems so they can improve equitable access to healthcare for the long term. As a core priority embedded in our ESG ESG Environmental, social and governance strategy, global health equity is an imperative for Johnson & Johnson and for our stakeholders.

Health equity is the absence of unfair, avoidable and remediable differences in health status among groups of people. Health equity is achieved when everyone can attain their full potential for health and well-being.2

Facts About Health Inequities

18.1
People in low-income countries live 18.1 years less than people from high-income countries.3
3x
In the U.S., Black women are three times more likely to die from a pregnancy-related
cause.4
3x
Girls aged 15 – 19 in sub-Saharan Africa contract HIV HIV Human immunodeficiency virus at a rate three times higher than boys the same age.2
90%
Of the more than 1 billion people with a vision impairment worldwide, 90% live in low- and middle-income countries (LMICs).5
18.1
People in low-income countries live 18.1 years less than people from high-income countries.3
3x
In the U.S., Black women are three times more likely to die from a pregnancy-related
cause.4
3x
Girls aged 15 – 19 in sub-Saharan Africa contract HIV HIV Human immunodeficiency virus at a rate three times higher than boys the same age.2
90%
Of the more than 1 billion people with a vision impairment worldwide, 90% live in low- and middle-income countries (LMICs).5
We continue to expand our transformational medical innovation strategy to address additional diseases within our therapeutic areas, improve our early stage innovation capabilities and embrace advances in data science to drive effective, targeted and equitable solutions to diverse health needs. The COVID-19 pandemic demonstrated how rapidly the world can be disrupted by a major health crisis and how systemic inequities can adversely impact healthcare for all. However, COVID-19 also brought everyone at Johnson & Johnson together to harness our entire organization, knowledge, resources, and many longstanding and new partnerships to curb the pandemic through our COVID-19 vaccine and create a better, healthier future for all.
Jennifer Taubert
Executive Vice President, Worldwide Chairman, Pharmaceuticals, Johnson & Johnson

Read on in this section to learn about our progress in:

Back to Top